Abstract
Various grades of adverse events are associated with sorafenib and have recently been considered as a surrogate of response in patients with advanced hepatocellular carcinoma. The aim of this prospective study was to measure the efficacy of a sorafenib dose reduction regimen, adjusted on patient's tolerability, and aimed at increasing the exposure to the drug.
| Lingua originale | Inglese |
|---|---|
| pagine (da-a) | N/A-N/A |
| Rivista | Liver International |
| Numero di pubblicazione | Dicembre |
| DOI | |
| Stato di pubblicazione | Pubblicato - 2015 |
All Science Journal Classification (ASJC) codes
- Epatologia
Keywords
- adverse events
- hepatocellular carcinoma
- sorafenib
- tolerable adverse events protocol
- toxicity
- tumor response
Fingerprint
Entra nei temi di ricerca di 'Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma'. Insieme formano una fingerprint unica.Cita questo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver